US EditionThirtyFiveBio Closes Bridge Financing
Summary by FinSMEs
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
ThirtyFiveBio Closes Bridge Financing
ThirtyFiveBio, an Oxford, UK-based biotechnology company developing small molecule inhibitors for the treatment of gastrointestinal (GI) disease, closed a Bridge financing of an undisclosed amount. The round included participation from AbbVie Ventures, Canaan and new investor Mayewell Capital. The company intends to use the funds to support the continued development of the its GPR35 inhibitor program, which […] The post ThirtyFiveBio Closes Bri…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
